Hoth Therapeutics Files 10-Q, Remains Pre-Revenue Biotech

TL;DR

**HOTH is still a pre-revenue biotech burning cash; don't expect profits anytime soon.**

AI Summary

Hoth Therapeutics, Inc. (HOTH) reported no revenue for the quarter ended June 30, 2025, consistent with its pre-revenue biotechnology status. The company continues to operate at a net loss, reflecting ongoing research and development expenditures. No specific net income figures or percentage changes were provided in the excerpt, but the company's status as a 'smaller reporting company' and 'non-accelerated filer' suggests limited financial scale. Key business changes were not detailed in the provided text, but the company's primary focus remains on pharmaceutical preparations. Risks include the inherent uncertainties of drug development and the need for significant capital, though specific risk factors were not enumerated here. The strategic outlook, while not explicitly stated, involves advancing its therapeutic pipeline, as implied by its industry classification. The company maintains its listing on The Nasdaq Stock Market LLC under the symbol HOTH.

Why It Matters

For investors, Hoth Therapeutics' continued pre-revenue status means its valuation is entirely speculative, tied to future drug development milestones rather than current financial performance. Employees face job security tied to successful clinical trials and funding, while customers (future patients) await potential new therapies. The broader market sees HOTH as a small player in the highly competitive pharmaceutical preparations sector, where larger firms like Pfizer or Johnson & Johnson dominate. Its success or failure could slightly impact the biotech sub-sector's sentiment for early-stage companies.

Risk Assessment

Risk Level: high — Hoth Therapeutics is a 'smaller reporting company' and 'non-accelerated filer' with no revenue, indicating a high-risk profile typical of early-stage biotechnology firms. The absence of revenue means the company relies entirely on external funding or existing capital to sustain operations and drug development, posing significant liquidity risks.

Analyst Insight

Investors should approach Hoth Therapeutics with extreme caution, recognizing it as a highly speculative investment. Only those with a high-risk tolerance and a long-term horizon, willing to bet on potential future drug approvals, should consider a position. Monitor R&D updates and financing activities closely.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (Hoth Therapeutics reported no revenue for the quarter ended June 30, 2025, indicating its pre-commercial stage.)
• 10-Q — Form Type (The company filed a Quarterly Report, providing an update on its financial condition and operations for the quarter.)
• 001-38803 — Commission File Number (This unique identifier is used by the SEC for Hoth Therapeutics' filings.)
• 20250630 — Conformed Period of Report (The financial data covers the period ending June 30, 2025.)
• 251206903 — Film Number (An internal SEC identifier for the filing.)

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — registrant filing 10-Q
• The Nasdaq Stock Market LLC (company) — exchange where HOTH common stock is registered
• 001-38803 (regulator) — Commission File Number
• June 30, 2025 (date) — end of the quarterly period reported
• Nevada (company) — state of incorporation for Hoth Therapeutics
• 1177 Avenue of the Americas (company) — business address of Hoth Therapeutics
• New York (company) — city of Hoth Therapeutics' business address
• 82-1553794 (company) — IRS Employer Identification No. for Hoth Therapeutics
• 03 Life Sciences (company) — organization name associated with the filer
• 2025-08-12T00:00:00.000Z (date) — filing date of the 10-Q

FAQ

Risk Factors

• Need for Significant Capital [high — financial]: As a pre-revenue biotechnology company, Hoth Therapeutics requires substantial capital to fund its research and development activities, clinical trials, and eventual commercialization. Failure to secure adequate funding could impede or halt its progress.
• Drug Development Uncertainty [high — operational]: The development of pharmaceutical products is inherently uncertain and subject to numerous risks, including the failure to demonstrate safety and efficacy in clinical trials, regulatory hurdles, and market acceptance. These uncertainties can lead to significant delays and increased costs.
• Regulatory Approval Process [high — regulatory]: Obtaining regulatory approval from bodies like the FDA is a complex, lengthy, and expensive process. Delays or failures in this process can significantly impact the company's ability to bring its products to market.

Industry Context

Hoth Therapeutics operates within the pharmaceutical preparations industry, a sector characterized by high research and development costs, lengthy product development cycles, and significant regulatory oversight. The competitive landscape includes numerous companies, from large established pharmaceutical giants to smaller biotech firms, all vying for market share and therapeutic breakthroughs. Key industry trends involve advancements in drug discovery technologies, personalized medicine, and increasing focus on biologics and novel therapeutic modalities.

Regulatory Implications

As a biotechnology company, Hoth Therapeutics is subject to stringent regulatory requirements from agencies like the FDA. The process of drug development, clinical trials, and eventual market approval involves significant compliance obligations. Any missteps or delays in regulatory processes can have severe financial and operational consequences.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-06-30: Quarterly Period End — This date marks the end of the reporting period for the 10-Q filing, providing financial and operational data up to this point.
• 2025-08-12: 10-Q Filing Date — The date the company officially filed its Quarterly Report with the SEC, making the information publicly available.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a continuing disclosure of financial and other information for the issuer's fiscal quarter. (This filing provides the latest financial and operational update for Hoth Therapeutics.)

Smaller Reporting Company

A company that meets certain criteria related to public float and annual revenue, allowing for scaled disclosure requirements. (Indicates Hoth Therapeutics has a limited financial scale and may have less stringent reporting obligations.)

Non-accelerated filer

A type of filer that is not a large accelerated filer or an accelerated filer, typically indicating a smaller company with less public float and revenue. (Further emphasizes Hoth Therapeutics' smaller size and potentially less extensive financial reporting compared to larger companies.)

Pharmaceutical Preparations

Products manufactured for use as medicines or drugs. (This is the Standard Industrial Classification (SIC) code for Hoth Therapeutics, indicating its primary business focus.)

Year-Over-Year Comparison

The provided 10-Q filing for the period ending June 30, 2025, indicates no revenue, consistent with the company's pre-commercial biotechnology status. Specific comparative figures for net income, margins, or asset/debt levels against the prior year's filing are not detailed in this excerpt. However, the company's continued operation as a smaller reporting company and non-accelerated filer suggests a consistent financial scale. No new specific risk factors were enumerated in the provided text, but the inherent risks of drug development and capital requirements remain central.

From the Filing

0001213900-25-074968.txt : 20250812 0001213900-25-074968.hdr.sgml : 20250812 20250812161547 ACCESSION NUMBER: 0001213900-25-074968 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250812 DATE AS OF CHANGE: 20250812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 251206903 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 10-Q 1 ea0249801-10q_hoth.htm QUARTERLY REPORT     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  10-Q   (Mark One) ☒   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the Quarterly Period Ended: June 30, 2025   ☐   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from:   Commission File Number: 001-38803   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   82-1553794 (State or other jurisdiction of   (I.R.S. Employer incorporation or organization)   Identification No.)   1177 Avenue of the Americas , 5 th Floor , Suite 5066 , New York , NY   10036 (Address of principal executive offices)   (Zip Code)   (646) 756-2997 (Registrant’s telephone number, including area code)   Not applicable (Former name, former address and former fiscal year, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐   Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.   Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒     Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒   The number